Allstate

ALL · NYSE

$249.91+$3.06 (+1.24%)TodayMarket closed · Oct 20, 7:45 PM ET

Prev close $246.85

ALL analyst rating

HoldConsensus of 21 analysts over the last 12 months. 38% rate it a buy.

Strong buy1
Buy7
Hold10
Underperform2
Sell1

12-month price target · 25 analysts

Average $272.28 (+9.0% upside)

Low: $132.64
Now: $249.91
High: $352.80

Upgrades and downgrades

The latest rating actions, newest first

ALL analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 12, 2026	Upgrade	Underweight → Equal-Weight	$250.00 → $236.00	60%
Keefe, Bruyette & Woods	Oct 12, 2026	Maintains	Underperform	$250.00 → $232.00	68%
Mizuho	Oct 7, 2026	Maintains	Outperform	$300.00 → $295.00	58%
Barclays	Oct 7, 2026	Maintains	Underweight	$226.00 → $221.00	61%
Morgan Stanley	Oct 6, 2026	Maintains	Equal-Weight	$265.00 → $240.00	49%
Citigroup	Oct 2, 2026	Maintains	Sell	$240.00 → $215.00	59%
Goldman Sachs	Oct 1, 2026	Maintains	Neutral	$280.00 → $250.00	55%
Mizuho	Sep 18, 2026	Maintains	Outperform	$297.00 → $300.00	58%
Mizuho	Sep 16, 2026	Maintains	Outperform	$300.00 → $297.00	58%
Argus Research	Aug 28, 2026	Downgrade	Buy → Hold	—	59%

The case for and against

Updated Oct 14, 2026

Bull case

Allstate is benefiting from a successful turnaround in personal auto, where aggressive rate increases, tighter underwriting, and selective policy attrition restored margin and produced combined ratios well below historical norms, with an 88.5% underlying combined ratio year-to-date and reported EPS of $8.99 versus $6.03 consensus. Its outlook is further supported by accelerating policy growth, a strong homeowners opportunity as peers retreat or lack margin, and management’s confidence that it can trade modest margin for faster growth while still earning attractive returns. Capital strength also reinforces the case, with $1.3 billion returned to shareholders, $2.6 billion remaining under the $4 billion repurchase authorization, and deployable capital rising to $9.5 billion.

Bear case

Allstate is vulnerable to a thesis built on mounting competitive pressure, which can compress margins in its core personal auto and broader property-casualty business, especially when products are distributed through about 6,000 exclusive agents. Its earnings quality also faces risk from unexpected changes in claim cost inflation, which can quickly erode underwriting profitability if loss trends outpace pricing and reserves. In addition, asbestos exposure and financial market sensitivity in its life operations add litigation and investment risk, making the overall fundamental outlook less attractive.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.